1
2
3
We don't have analytics for this instrument yet. You can contribute!
Please log in and be the first author to write an article about this instrument!
Minerva Neurosciences, Inc. (NASDAQ)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sessione trading (UTC)
Aperta ora
Chiusa ora
Chiude
Apre
alle
-
Gli orari di apertura sono indicati nel tuo fuso orario locale
(UTC)
Ticker | NERV |
Valore del contratto | 100 shares |
Leva massima | 1:5 |
Storico degli swap
Data | Short Swap (%) | Long Swap (%) | No data |
---|
Volume minimo di una transazione | 0.01 lotto |
Volume massimo di una transazione | 100 lotti |
Margine di copertura | 50% |